Unknown

Dataset Information

0

Synthetic switch-based baculovirus for transgene expression control and selective killing of hepatocellular carcinoma cells.


ABSTRACT: Baculovirus (BV) holds promise as a vector for anticancer gene delivery to combat the most common liver cancer-hepatocellular carcinoma (HCC). However, in vivo BV administration inevitably results in BV entry into non-HCC normal cells, leaky anticancer gene expression and possible toxicity. To improve the safety, we employed synthetic biology to engineer BV for transgene expression regulation. We first uncovered that miR-196a and miR-126 are exclusively expressed in HCC and normal cells, respectively, which allowed us to engineer a sensor based on distinct miRNA expression signature. We next assembled a synthetic switch by coupling the miRNA sensor and RNA binding protein L7Ae for translational repression, and incorporated the entire device into a single BV. The recombinant BV efficiently entered HCC and normal cells and enabled cis-acting transgene expression control, by turning OFF transgene expression in normal cells while switching ON transgene expression in HCC cells. Using pro-apoptotic hBax as the transgene, the switch-based BV selectively killed HCC cells in separate culture and mixed culture of HCC and normal cells. These data demonstrate the potential of synthetic switch-based BV to distinguish HCC and non-HCC normal cells for selective transgene expression control and killing of HCC cells.

SUBMITTER: Lin MW 

PROVIDER: S-EPMC6125686 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synthetic switch-based baculovirus for transgene expression control and selective killing of hepatocellular carcinoma cells.

Lin Mei-Wei MW   Tseng Yen-Wen YW   Shen Chih-Che CC   Hsu Mu-Nung MN   Hwu Jih-Ru JR   Chang Chin-Wei CW   Yeh Chung-Ju CJ   Chou Min-Yuan MY   Wu Jaw-Ching JC   Hu Yu-Chen YC  

Nucleic acids research 20180901 15


Baculovirus (BV) holds promise as a vector for anticancer gene delivery to combat the most common liver cancer-hepatocellular carcinoma (HCC). However, in vivo BV administration inevitably results in BV entry into non-HCC normal cells, leaky anticancer gene expression and possible toxicity. To improve the safety, we employed synthetic biology to engineer BV for transgene expression regulation. We first uncovered that miR-196a and miR-126 are exclusively expressed in HCC and normal cells, respect  ...[more]

Similar Datasets

| S-EPMC8463442 | biostudies-literature
| S-EPMC3480355 | biostudies-literature
| S-EPMC6182168 | biostudies-literature
| S-EPMC5554962 | biostudies-literature
| S-EPMC3813527 | biostudies-literature
| S-EPMC4426788 | biostudies-literature
| S-EPMC3964311 | biostudies-literature
| S-EPMC6589740 | biostudies-literature
| S-EPMC3958484 | biostudies-literature